全文获取类型
收费全文 | 1301319篇 |
免费 | 96956篇 |
国内免费 | 3984篇 |
专业分类
耳鼻咽喉 | 18350篇 |
儿科学 | 42454篇 |
妇产科学 | 38046篇 |
基础医学 | 190074篇 |
口腔科学 | 35786篇 |
临床医学 | 111784篇 |
内科学 | 255134篇 |
皮肤病学 | 26727篇 |
神经病学 | 100590篇 |
特种医学 | 51195篇 |
外国民族医学 | 384篇 |
外科学 | 200338篇 |
综合类 | 31257篇 |
现状与发展 | 13篇 |
一般理论 | 304篇 |
预防医学 | 94444篇 |
眼科学 | 29718篇 |
药学 | 100495篇 |
36篇 | |
中国医学 | 4189篇 |
肿瘤学 | 70941篇 |
出版年
2018年 | 12849篇 |
2016年 | 10946篇 |
2015年 | 12860篇 |
2014年 | 17620篇 |
2013年 | 25774篇 |
2012年 | 35596篇 |
2011年 | 38119篇 |
2010年 | 22562篇 |
2009年 | 21074篇 |
2008年 | 36244篇 |
2007年 | 39229篇 |
2006年 | 39734篇 |
2005年 | 38977篇 |
2004年 | 37146篇 |
2003年 | 36189篇 |
2002年 | 35657篇 |
2001年 | 58672篇 |
2000年 | 60149篇 |
1999年 | 51248篇 |
1998年 | 14603篇 |
1997年 | 13180篇 |
1996年 | 13312篇 |
1995年 | 12600篇 |
1994年 | 11976篇 |
1993年 | 11008篇 |
1992年 | 41114篇 |
1991年 | 40486篇 |
1990年 | 39961篇 |
1989年 | 38771篇 |
1988年 | 36178篇 |
1987年 | 35402篇 |
1986年 | 33753篇 |
1985年 | 32156篇 |
1984年 | 23941篇 |
1983年 | 20822篇 |
1982年 | 12381篇 |
1981年 | 10935篇 |
1979年 | 22641篇 |
1978年 | 15879篇 |
1977年 | 13729篇 |
1976年 | 12970篇 |
1975年 | 14201篇 |
1974年 | 16683篇 |
1973年 | 16076篇 |
1972年 | 15320篇 |
1971年 | 14229篇 |
1970年 | 13215篇 |
1969年 | 12731篇 |
1968年 | 11979篇 |
1967年 | 10478篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
目的 观察结肠癌HCT116细胞健脾消癌方的条件培养液对HUVEC细胞管腔形成的影响,从PI3K/Akt生物轴调控角度探讨其作用机制。方法 培养HCT116细胞,细胞设3组:对照组,健脾消癌方组(加入15%健脾消癌方含药血清)及人参皂苷Rg3组;制备HCT116细胞健脾消癌方条件培养液(分组及制备方法见实验方法),用条件培养液干预HUVEC(脐静脉内皮细胞,Human Umbilical Vein Endothelial Cells),Matrigel基质胶法检测HCT116细胞健脾消癌方条件培养液对HUVEC小管形成的影响。随后采用蛋白免疫印迹法(Western blot)检测各组HCT116细胞磷脂酰肌醇3-激酶(PI3K)、蛋白激酶B(Akt)、p-Akt、VEGF(血管内皮生长因子,Vascular endothelial growth factor)蛋白表达。最后在结肠癌HCT116荷瘤小鼠中验证健脾消癌方对肿瘤生长速度的影响,并经瘤组织VEGF蛋白表达、CD31免疫组化染色检测肿瘤内血管生成情况。结果 模型组HUVEC细胞管腔形成较空白血清组显著增加(P<0.05);健脾消癌方组及人参皂苷Rg3组较模型组HUVEC细胞管腔形成显著减少(P<0.01)。p-Akt和VEGF蛋白表达水平模型组高于空白血清组(P<0.05),健脾消癌方组及人参皂苷Rg3组显著低于模型组(P<0.01);PI3K、Akt蛋白表达量组间差异无统计学意义。与对照组比较,模型组荷瘤小鼠肿瘤体积显著性增大,瘤组织内VEGF表达、CD31阳性面积显著性增加,差异有统计学意义(P<0.05);与模型组比较,健脾消癌方组及人参皂苷Rg3组荷瘤小鼠肿瘤体积显著减小,瘤组织内VEGF表达、CD31阳性面积降低,差异有统计学意义(P<0.05)。结论 健脾消癌方可抑制肿瘤的血管生成和生长,其作用机制可能与PI3K/Akt生物轴调控VEGF表达有关。 相似文献
2.
3.
4.
5.
6.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
7.
Timothy J. Cordingley Mark A.G. Wilson Kathryn M. Weston 《Health & social care in the community》2022,30(1):353-359
Vaccination is a vital health care initiative to prevent individual and population infection. To increase vaccination rates the federal government implemented the ‘No Jab, No Pay’ policy, where eligibility for several government benefits required children to be fully vaccinated by removing ‘conscientious objections’ and expanding the age range of children whose families receive benefits. This study assesses the impact of this policy at a local area within a single medical practice community in NSW, Australia. A retrospective clinical audit was performed between 2012 and 2017 on a single general practice's vaccination records for children ≤19 years. Catch-up vaccinations were assessed based on age at vaccination. Incidence of catch-up vaccinations was assessed for each of four years before and two years after the implementation of the ‘No Jab, No Pay’ policy in January 2016, along with the age of children and vaccination(s) given. Catch-up vaccinations were assessed temporally either side of implementation of ‘No Jab, No Pay’. Comparing the average annual vaccination catch-up incidence rate of 6.2% pre-implementation (2012–2015), there was an increase to 9.2% in 2016 (p < .001) and 7.8% in 2017 (p = .027). Secondary outcome measurement of catch-up vaccination incidence rates before (2012–2015) and after (2016–2017) ‘No Jab, No Pay’ implementation showed statistically significant increases for children aged 8–11 years (3.2%–5.6%, p = .038), 12–15 years (7.5%–14.7%, p < .001) and 16–19 years (3.3%–10.2%, p < .001) along with a statistically significant reduction in children aged 1–3 years (11.4%–6.2%, p = .015). Also, catch-up rates for DTPa significantly increased after program implementation. This study demonstrates that the Australian federal government vaccination policy ‘No Jab, No Pay’ was coincident with an increase in catch-up vaccinations within a rural NSW community served by one medical practice, especially for older children. 相似文献
8.
9.
Platelets are needed to prevent or arrest bleeding and aggregate at the site of injury upon vascular damage. Platelets express receptors for estrogens which might affect the function of the platelets and their hemostatic ability. The aim was to identify possible differences in platelet function related to age, gender, and phases of the menstrual cycle by use of impedance aggregometry with Multiplate. In the first part of the study, platelet function was assessed in 60 healthy individuals (30 men and 30 women) in each of three age groups (20–25, 40–45, and 60–65 years). In the second part of the study, the platelet function was analyzed on four occasions during the menstrual cycle in women without oral contraceptives (OCs) (n = 17) and compared to 19 women on OCs and 18 men of similar age (20–40 years). For the women on OCs, aggregation was analyzed once during the tablet-free week and once late during the period with OCs. The men were sampled once. Women of younger age (<45 years) had significantly higher agonist-induced aggregation response than both men and post-menopausal women (60–65 years). The agonist-induced aggregation response did not differ between phases of the menstrual cycle or OC use. The results suggest that estradiol and/or progesterone affect spontaneous aggregation since it was found to be lowest in the mid-luteal phase. Spontaneous aggregation was significantly lower in women on OCs than in both men and women without OCs. Our findings indicate that fertile age is associated with higher aggregation response capacity of the platelets, possibly to prevent excessive bleeding during menstruation, but this response capacity is not altered during the menstrual cycle or by use of OCs. 相似文献
10.